This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 18, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio and slide webcast of its analyst and investor seminar, focusing on the company's commercial product projections and future growth opportunities on
Friday, September 21, 2012. Lectures will be provided by a number of ViroPharma representatives.
The seminar, entitled "
Broadening Horizons," will be held from
9:00 A.M. until 12:45 P.M. Eastern Time on
Friday, September 21, 2012. Among the topics ViroPharma will discuss are: plans and opportunities for furthering Cinryze
® (C1 esterase inhibitor [human]) growth in
North America; updates on launch progress and projections for Cinryze, Buccolam
® (midazolam, oromucosal solution),
® (hydrocortisone, modified release tablet) in the European Union; development pipeline updates including interim data from select clinical studies; and a financial overview, including longer term financial guidance.
"We are excited to be in position to not only provide continued growth with our cornerstone product, Cinryze, here in
North America and in
Europe, but also to be moving ahead on numerous other commercial products and development opportunities to deliver sustained growth well into the back half of the decade and beyond," commented
Vincent Milano, ViroPharma's president and chief executive officer. "We look forward to this event and sharing our plans with the investment community as they can begin to share in our vision of both the short and long term milestones in the path forward for ViroPharma."
A live webcast of the meeting may be accessed via the investor section of the ViroPharma corporate website,
http://www.viropharma.com. The archive of the meeting will be available through
October 31, 2012.
About Cinryze ® (C1 esterase inhibitor [human])Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product. In the U.S., Cinryze is approved by the FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In the E.U., the product is approved by the EMA for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. Cinryze is for intravenous use only.
Severe hypersensitivity reactions to Cinryze may occur. Thrombotic events have occurred in patients receiving Cinryze, and in patients receiving off-label high dose C1 inhibitor therapy. Monitor patients with known risk factors for thrombotic events. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.